<DOC>
	<DOCNO>NCT00400439</DOCNO>
	<brief_summary>This 2 arm study ass long term safety efficacy RO4607381 patient coronary heart disease coronary heart disease ( CHD ) risk equivalent complete study NC19453 . Patients eligible participate extension study continue treatment originally assign ie RO4607381 ( 900mg po ) placebo daily , concomitant daily atorvastatin ( 10 80mg po ) . The anticipated time study treatment 6 month post study NC19453 , target sample size approximately 100 individual .</brief_summary>
	<brief_title>A Long Term Extension Study NC19453 Evaluating Safety Efficacy RO4607381</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Dalcetrapib</mesh_term>
	<criteria>patient complete treatment study NC19453 . significant lymph node abnormality end study NC19453 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>